In a report released on April 24, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Next Science Ltd (NXSCF – Research Report), with a price target of A$0.85. The company’s shares closed last Tuesday at $0.48.
According to TipRanks, Shapiro is a 3-star analyst with an average return of 2.7% and a 46.67% success rate. Shapiro covers the Healthcare sector, focusing on stocks such as Impedimed Limited, Next Science Ltd, and Mayne Pharma Group.
Currently, the analyst consensus on Next Science Ltd is a Moderate Buy with an average price target of $0.51.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $0.78 and a one-year low of $0.39. Currently, Next Science Ltd has an average volume of 18.16K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Next Science Ltd is an Australia based company formed to commercialise and develop its Xbio technology, which is a non-toxic technology with efficacy in eradicating both biofilm based and free-floating bacteria. The company’s products includes SurgX Sterile wound Gel, Bactisure Surgical Lavage and Blast X Wound Gel.
